USFDA issues Form 483 with one Observation to Laurus Labs

The inspection was conducted from October 24th, 2022 to October 28th, 2022.

588
Form 483
Form 483

Last Updated on October 9, 2024 by The Health Master

Hyderabad: Laurus Labs today announced that the US Food and Drug Administration (USFDA) has concluded a PreApproval Inspection (PAI) with one observation at its manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh.

The inspection was conducted from October 24th, 2022 to October 28th, 2022.

“We have been issued a Form 483 with one observation.” “The observation is procedural in nature,” the company stated in a BSE filing.

At the conclusion of an inspection, a USFDA Form 483 is issued to firm management if an investigator(s) observes any conditions that, in their opinion, may constitute violations of the Food, Drug, and Cosmetic (FD&C) Act and related Acts.

“The company will address the observation within the stipulated timelines,” Laurus Labs said.

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. Anti-retroviral, Hepatitis C, and oncology medications are among the company’s primary focus areas.

Most of the Laurus Labs manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc.

USFDA issues form 483 with 17 observations to Lupin

USFDA issues form 483 with four observations to Alembic Pharma

USFDA issues 2 observations on Form 483 to Zydus Lifesciences

USFDA issues Form 483 to Indoco with zero observation

USFDA issues Form 483 with 11 observation to Biocon

USFDA issues Form 483 with 2 observation to Alembic

CDSCO Panel approves Tofacitinib Ointment 2% to Continue Clinical Trial Study

USFDA gives final approval for Paclitaxel injection

This State Pharmacy Council to appoint Pharmacy Inspectors

Medical Stores पर कार्रवाई: नशीली दवाई बेचने पर Licenses cancel, suspend

Two persons arrested in fake BP medicine racket

NPPA extends time limit for submission of data of Drugs & Medical Devices

USFDA gives approval to this Blood Cancer therapy

NPPA fixes retail price for diabetes drug combination Dapagliflozin & Sitagliptin

USFDA grants final approval for Micafungin for injection

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news